Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
A double-blind, placebo-controlled, randomised, multi-centre, 3-way cross-over, single-dose phase II study to investigate the local and systemic effects of inhaled AZD8683 in patients with chronic obstructive pulmonary disease (COPD)
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinical diagnosis of COPD
Current or ex-smokers
FEV1 40 - 80% of the predicted normal value (post-bronchodilator) and post-bronchodilator FEV1/FVC \< 70%
You may not be if
Any clinically significant disease or disorder
Any clinically relevant abnormal findings at screening examinations
